Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
暂无分享,去创建一个
J. Forbes | M. Buyse | G. Sauter | J. Mackey | V. Valero | W. Eiermann | G. von Minckwitz | D. Slamon | M. Press | P. Fumoleau | J. Rolski | M. Pegram | Miguel Martín | A. Riva | T. Pieńkowski | A. Jagiełło-Gruszfeld | H. Roché | J. Crown | Z. Mršić-Krmpotić | H. Taupin